Edition:
United States

Cytokinetics Inc (CYTK.O)

CYTK.O on Nasdaq

12.45USD
16 Aug 2017
Change (% chg)

-- (--)
Prev Close
$12.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
687,934
52-wk High
$17.20
52-wk Low
$8.51

Latest Key Developments (Source: Significant Developments)

Cytokinetics Q2 loss per share $0.60
Wednesday, 2 Aug 2017 04:00pm EDT 

Aug 2 (Reuters) - Cytokinetics Inc :Cytokinetics Inc reports second quarter 2017 financial results.Q2 revenue $3.1 million versus $5.8 million.Q2 loss per share $0.60.Q2 revenue view $8.3 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S.  Full Article

Cytokinetics announces positive results from phase 2 trial of Omecamtiv Mecarbil
Wednesday, 2 Aug 2017 07:30am EDT 

Aug 2 (Reuters) - Cytokinetics Inc ::Cytokinetics announces positive results from phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure.Cytokinetics announces positive results from phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure.Cytokinetics inc - ‍company is eligible to earn $10 million milestone payment from amgen upon first patient dosing in Japan in phase 3 outcomes trial​.Cytokinetics inc - ‍phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure has met its pharmacokinetic primary endpoint​.Cytokinetics inc - ‍phase 2 clinical trial demonstrated statistically significant improvements in systolic ejection time (set), a secondary endpoint​.Cytokinetics inc - ‍cytokinetics is eligible to earn a $10 million milestone payment from amgen upon first dosing of a patient in Japan in Galactic-Hf​.  Full Article

Cytokinetics announces start of FORTITUDE-ALS
Thursday, 27 Jul 2017 07:30am EDT 

July 27 (Reuters) - Cytokinetics Inc :Cytokinetics announces start of fortitude-als, a phase 2 clinical trial of ck-2127107 in patients with amyotrophic lateral sclerosis.  Full Article

Cytokinetics reports baseline data from first cohort of phase 2 clinical trial of ck-2127107 in patients with SMA
Wednesday, 5 Jul 2017 07:30am EDT 

July 5 (Reuters) - Cytokinetics Inc ::Cytokinetics announces baseline data from first cohort of phase 2 clinical trial of ck-2127107 in patients with sma.Cytokinetics -screen failures in cohort 1 primarily due to hfmse score that was either too high in ambulatory patients or too low in non-ambulatory patients.Cytokinetics - there were no statistically significant differences otherwise in baseline demographics of enrolled patients compared to screen failures.Cytokinetics - screen failures in cohort 1 primarily due to hfmse score that was either too high in ambulatory patients or too low in non-ambulatory patients.  Full Article

Cytokinetics says Ching Jaw joined co as senior vice president, CFO on June 26, 2017
Thursday, 29 Jun 2017 04:50pm EDT 

June 29 (Reuters) - Cytokinetics Inc :Cytokinetics Inc says Ching Jaw joined Cytokinetics as senior vice president, chief financial officer on june 26, 2017 - sec filing.  Full Article

Cytokinetics starts phase 1B clinical trial of CK-2127107 in elderly subjects
Thursday, 29 Jun 2017 07:30am EDT 

June 29 (Reuters) - Cytokinetics Inc :Cytokinetics announces start of phase 1B clinical trial of CK-2127107 in elderly subjects with limited mobility.Cytokinetics Inc - clinical trial is expected to enroll at least 60 subjects in United States who are 70 to 89 years of age with limited mobility.  Full Article

Cytokinetics prices 5.26 mln common shares at $14.25 per share
Monday, 8 May 2017 09:49pm EDT 

May 8 (Reuters) - Cytokinetics Inc :Cytokinetics announces pricing of public offering of common stock.Says public offering of 5.26 million common shares priced at $14.25per share.  Full Article

Cytokinetics announces proposed public offering of common stock
Monday, 8 May 2017 04:29pm EDT 

May 8 (Reuters) - Cytokinetics Inc :Cytokinetics announces proposed public offering of common stock.Cytokinetics Inc says $75 million of its common stock in an underwritten public offering.  Full Article

Cytokinetics Q1 loss per share $0.62
Thursday, 27 Apr 2017 04:00pm EDT 

April 27 (Reuters) - Cytokinetics Inc ::Cytokinetics, inc. Reports first quarter 2017 financial results.Q1 revenue $4.2 million versus $8.4 million.Q1 loss per share $0.62.Q1 earnings per share view $-0.61, revenue view $20.8 million -- Thomson Reuters I/B/E/S.  Full Article

Cytokinetics announces start of second cohort in Phase 2 clinical trial of CK-2127107
Wednesday, 29 Mar 2017 07:30am EDT 

Cytokinetics Inc :Cytokinetics announces start of second cohort in phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy.  Full Article

BRIEF-Cytokinetics Q2 loss per share $0.60

* Cytokinetics Inc reports second quarter 2017 financial results